Your Health, We Care
Exkivity is a targeted therapeutic drug for NSCLC patients with EGFR exon 20 insertion mutation, which has shown significant efficacy in clinical trials.
In October 2023, Takeda Pharmaceuticals announced that it would cooperate with the US FDA to voluntarily withdraw the marketing authorization of Exkivity in the United States. Patients and doctors should consider multiple factors when choosing treatment plans to develop personalized treatment plans that are most suitable for patients.
Exkivity is a targeted drug for the treatment of specific types of lung cancer, ···【more】
Release date：2024-08-06Recommended：171
Exkivity is available in multiple versions, including innovator versions and mul···【more】
Release date：2024-08-06Recommended：157
Exkivity, also known as Mobocertinib, is a novel targeted drug that offers hope ···【more】
Release date：2024-08-06Recommended：171
